Loading...
NPI 1811926769 · Southlake, TX · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jawad Qureshi is a ophthalmology physician provider located in Southlake, Texas. This profile covers 19 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jawad Qureshi |
| Address | 305 Morrison Park Dr Ste 100 |
| City | Southlake |
| State | TX |
| ZIP | 76092 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | July 2, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.6M |
| Medicaid | $1.7K |
This provider’s Medicare revenue is heavily concentrated in a small set of high-cost ophthalmology injections and exam codes: the precomputed top 3 Medicare codes account for 90.0% of total Medicare revenue, with J2777 ($4.9M, 65.2%) and J0178 ($1.3M, 17.5%) dominating receipts and 92014 contributing the remainder. The code mix (intravitreal injections J2777 and J0178 plus comprehensive established eye exams 92014) indicates a service line focused on medical retina care and frequent in-office therapeutic injections paired with routine ophthalmic follow-up.
JAWAD QURESHI is effectively a Medicare-focused provider by scale: lifetime Medicare revenue is $7.6M versus total Medicaid revenue of $1.7K, meaning Medicaid is negligible in the revenue mix and this practice operates as a near single-payer (Medicare) revenue stream. The Medicaid activity that does exist is tiny relative to Medicare and concentrated in established-patient exams and retinal imaging (92014 and 92134).
J2777 (faricimab) billing is an extreme national outlier: the provider reports $4.9M from J2777, ranks #5 of 2039 providers nationally and is flagged as a 100th percentile extreme outlier. This ranking and revenue share (65.2% of Medicare revenue) mark the provider as a major national-volume prescriber/administrator of this specific biologic relative to peers.
92014 volume is also an extreme outlier nationally: the practice shows 5.6K claims and $553.5K revenue from 92014, ranking #3 of 35415 providers and described as 100th percentile extreme outlier. That combination of very high exam volume plus high-volume intravitreal injection codes reinforces a workflow model built around frequent follow-up and procedural retinal care.
J0178 (aflibercept) activity is significant but not exceptional: it generated $1.3M (17.5% of Medicare revenue), ranks #563 of 3204 providers (82th percentile) and is characterized as typical, unremarkable volume. Together with J2777, the two anti-VEGF/anti-PD therapies form the procedural backbone of the practice’s revenue rather than general ophthalmic office visits or minor procedures.
The provider shows several other procedure codes at markedly high national percentiles for volume in retina diagnostics and procedures—67028 (injection into vitreous) ranks in the 99th percentile and 92134 (retinal imaging) is a 100th percentile extreme outlier—supporting a high-throughput, retina-centric clinical operation that combines injections, diagnostic imaging, and surgical procedures. These patterns point to a specialized retinal practice rather than a general ophthalmology office.
Competitive standing across codes is mixed: for J2777 and 92014 the provider is a dominant national outlier (top ranks and 100th percentile), while for J0178, J7999, and several E/M codes the provider is a typical or notably above-typical participant. This suggests exceptional concentration and market prominence specifically for faricimab administration and high-volume established-patient exam throughput but routine participation in other service lines.
The provider has long tenure on file, with NPI enumeration dated 2006-07-02 (roughly 20 years ago), indicating an established practice presence in Southlake, TX. That longevity, together with concentrated high-volume billing in retina therapies and exams, is consistent with a mature specialty practice that has built scale in a narrow set of high-revenue services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
19 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 170,350 | $30 | $4.9M |
| J0178 | Injection, aflibercept, 1 mg | 1,950 | $680 | $1.3M |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 5,650 | $100 | $553.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 3,920 | $100 | $379.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 5,560 | $30 | $172.4K |
| J7999 | Compounded drug, not otherwise classified | 720 | $70 | $50.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 550 | $70 | $36.5K |
| 92004 | The provider performs a comprehensive level ophthalmological evaluation of a new patient and initiates a diagnostic and treatment program for one or more visits. | 280 | $110 | $31K |
| 67042 | In this procedure, the provider removes vitreous humor, the gelatinous material that gives shape to the eye, using a mechanical cutting tool. He removes the internal limiting membrane of the retina… | 30 | $910 | $25.5K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 150 | $110 | $15.6K |
Showing 1–10 of 19
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
19 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 37 | 210 | 610 | $690 | $694.9K |
| J2777 | 2 | 140 | 7,470 | $30 | $479.2K |
| 67028 | 4 | 290 | 510 | $90 | $73K |
| 67042 | 34 | 90 | 20 | $1,150 | $41.3K |
| 67036 | 55 | 70 | 20 | $1,000 | $29.1K |
| 67210 | 26 | 30 | 40 | $370 | $25.7K |
| 92235 | 55 | 160 | 60 | $100 | $21.3K |
| 92014 | 1 | 2,700 | 100 | $80 | $21K |
| 99214 | 3,024 | 32,500 | 110 | $80 | $17.6K |
| J7999 | 8 | 140 | 90 | $80 | $14.4K |
Showing 1–10 of 19
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 20 | $80 | $1.3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 10 | $30 | $410 |
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 666 | 750 | 240 | $60 | $68.4K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 126 | 130 | 280 | $10 | $14.3K |
Other providers in the same ZIP code as Jawad Qureshi, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| C&l Esperanza Home Health Inc | TX | Personal Care Attendant | $0 | $14.8M |
| Choice Diagnostic Lab | TX | Clinical Medical Laboratory | $1.7M | $0 |
| Axis Surgery Center, LLC | TX | Ambulatory Surgical Clinic/Center | $1.1M | $0 |
| Lone Star Endoscopy Center, LLC | TX | Ambulatory Surgical Clinic/Center | $941.5K | $0 |
| Jennifer Mcintosh | TX | Family Nurse Practitioner | $886.8K | $0 |
| Health Imaging Partners, LLC | TX | Physiological Laboratory | $845.6K | $0 |
| Rene Leon | TX | Allergy Physician | $785.9K | $0 |
| Thr/stt Southlake Asc, LLC | TX | Ambulatory Surgical Clinic/Center | $650K | $0 |
| Angela Bowers | TX | Dermatology Physician | $507.9K | $0 |
| Robert Lyons | TX | Ophthalmology Physician | $389.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.